-
Democrat in key US Senate race denies sex assault claim
-
US leads international concern after China test-fires missile into Pacific
-
Samsung expects 1,800% leap in quarterly operating profit on AI boom
-
Close to tears and on his own as Ronaldo's World Cup dream ends
-
Russian strikes kill at least 26 in Kyiv region on eve of NATO summit
-
Argentina's gruelling World Cup schedule a concern for Scaloni
-
Ronaldo 'won't make rash decisions' following last World Cup game
-
Race to recover bodies ahead of Venezuela quake cleanup
-
Paraguay govt slams lawmaker for racially abusing France's Mbappe
-
Egypt coach Hassan says Palestinian suffering 'a shame on the world'
-
US embraces Balogun World Cup reprieve as world seethes
-
NBA Kings waive six-time All-Star forward DeRozan
-
Spain win it late to give Ronaldo bitter end to World Cup career
-
Greaves and Hope centuries usher West Indies towards safety
-
Spain edge Portugal to end Ronaldo World Cup dream, US eye quarters
-
'I celebrated in bed' -- Norway's Solbakken stays grounded after beating Brazil
-
Spain win it late to bid farewell to Ronaldo at World Cup
-
Canada chooses Germany's TKMS to build new fleet of submarines
-
Trump's fireworks made Washington world's most polluted city
-
Mbappe condemns racist abuse by Paraguayan senator after World Cup clash
-
Stock markets meander as US tech stocks climb
-
FIFA chief forced to defend Balogun World Cup reprieve
-
Britain's Fery stuns Dimitrov, Paolini into Wimbledon quarters
-
Antetokounmpo says goodbye to Milwaukee in video
-
Russian strikes kill 24 in Kyiv region on eve of NATO summit
-
Fairytale Fery sinks Dimitrov to make Grand Slam history at Wimbledon
-
Trump touts latest White House renovation: a new helipad
-
Canadian Artemis II crew member to retire from space agency
-
Fritz powers past Bublik, into Wimbledon last eight again
-
Prince Harry arrives in UK amid security spat
-
Ovechkin won't say next NHL season will be his last
-
'Agony' in Cuba amid third nationwide blackout in six months
-
Djokovic, Sinner aim to book Wimbledon blockbuster
-
For Trump's World Cup, 'America First' collides with world's game
-
Record fireworks display choked Washington in toxic smoke
-
England's World Cup campaign takes flight with Mexico win
-
Macron in Syria on first post-Assad visit by West European head of state
-
Tour de France stage record still 'far away' for Pogacar
-
US streamers launch new legal fight against French content rules
-
Infantino told Trump FIFA disciplinary body is 'independent'
-
EU tells France to amend social media ban law
-
Japanese forward Hachimura signs with Clippers: reports
-
Losses from latest French museum heist estimated at 4.5 mln euros
-
After designing Taylor Swift's wedding dress, Dior's Anderson returns to catwalk
-
Big defence spending, aid cuts: German cabinet approves budget
-
Russian strikes kill 22 in Kyiv region on eve of NATO summit
-
Microsoft cuts 4,800 jobs as it revamps Xbox
-
Pogacar back in 'special' yellow after Tour de France stage three victory
-
Don't let AI shape humanity's future: UN chief
-
Paolini ends Eala run ahead of Wimbledon wildcard clash
Lumira Ventures Announces Promotion of Suman Rao to Principal
Lumira Ventures, a leading North American life sciences investment firm dedicated to advancing healthcare innovation and enhancing patient outcomes, is pleased to announce the promotion of Suman Rao, Ph.D., to the role of Principal. This well-deserved promotion acknowledges her significant contributions to the firm's success and her steadfast commitment to fostering innovative healthcare solutions.
Dr. Rao joined Lumira Ventures in 2021 as an Associate and was promoted to Senior Associate in 2024, as she built out her skills and experience in all dimensions of the venture capital value chain. Her deep understanding of industry sectors like oncology and neuroscience coupled with her ability to foster strong relationships with entrepreneurs, co-investors, and industry stakeholders has made her a sought-after team member. Dr. Rao has been deeply involved with the firm's investments in Arclight Therapeutics, Congruence Therapeutics, and Damona Pharmaceuticals (as a board observer). Her contributions extend to being actively engaged in a number of the firm's strategic initiatives, including the Angelini Lumira Biosciences Fund and currently co-leading the Cancer Breakthrough Fund, a first-of-its-kind collaboration in Canada between a philanthropic organization (Terry Fox Foundation) and a VC firm with the goal to bring more capital to the mission of finding cures for cancers.
"We are delighted to elevate Suman to the role of Principal," said Peter van der Velden, Managing General Partner at Lumira Ventures. "Her growth at the firm and ability to take on more responsibility reflects our commitment to growing talent in-house and her dedication to developing the skills, expertise, and relationships that are the foundation of being a great VC."
"I am thrilled to be stepping into the role of Principal and grateful for the trust and support of my partners and colleagues," said Dr. Rao. "Together with an incredibly talented team, I look forward to supporting passionate entrepreneurs tackling some of medicine's biggest challenges today and building transformative companies."
Dr. Rao earned her Ph.D. in Experimental Medicine and her Bachelor's degree in Biochemistry from McGill University. Before joining Lumira Ventures, she completed a prestigious postdoctoral fellowship at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Rao also brings valuable experience from her time as a management consultant at L.E.K Consulting, where she provided strategic advice to biotech and pharma clients, further honing her expertise in the life sciences sector.
About Lumira Ventures
Lumira Ventures is a leading multi-stage life sciences investment firm operating across Toronto, Montréal, Vancouver, and Boston. As Canada's largest and most active dedicated life sciences venture capital investor, Lumira invests in first-in-class innovations in "secondary" geographies, partnering with mission-driven entrepreneurs to develop transformative therapeutics products and medical devices while generating strong financial returns and societal impact.
With a proven track record, Lumira Ventures has consistently delivered both financial success and transformative medical advancements. With portfolio companies having introduced over 50 biomedical innovations, improving the lives of over 1 billion patients worldwide and generating more than $70B in cumulative revenue.
For more information, please contact: [email protected]
www.lumiraventures.com
SOURCE: Lumira Ventures
M.King--AT